ICH E6 is the internationally harmonized guideline for Good Clinical Practice (GCP) developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). It sets the ethical and scientific standard for designing, conducting, recording, and reporting clinical trials involving human subjects.

What Is ICH E6?

ICH E6 provides a unified standard across the European Union, Japan, the United States, Canada, Switzerland, and other ICH member countries to facilitate mutual acceptance of clinical data by regulatory authorities. The guideline is organized into eight sections covering the principles of GCP, the responsibilities of Institutional Review Boards (IRBs), investigators, and sponsors, as well as requirements for the clinical trial protocol, the investigator’s brochure, and essential documents. The most recent revision, ICH E6(R3), introduces principles for digital technologies and decentralized trial elements.

Regulatory Framework

ICH E6(R3) reflects a modernization of the prior ICH E6(R2) guideline, emphasizing risk-based approaches to trial oversight, data integrity in electronic systems, and quality by design principles. The guideline is organized into three annexes: interventional clinical trials, non-traditional interventional trials, and observational studies. Regulatory authorities worldwide, including the FDA and EMA, reference ICH E6 as the benchmark for GCP compliance.

Key Requirements

The ICH E6 guideline outlines 13 fundamental principles of GCP, including that clinical trials should be conducted in accordance with the Declaration of Helsinki and that the rights, safety, and well-being of subjects prevail over scientific and societal interests. It requires that trial data be fully verifiable from source documents, that investigational products be manufactured according to Good Manufacturing Practice (GMP), and that quality assurance systems include independent audits and inspections.

Documentation

ICH E6 Section 8 specifies the essential documents that must be retained in the Trial Master File (TMF) before, during, and after trial conduct. These include the signed protocol and amendments, IRB approvals, investigator agreements, financial disclosure forms, case report forms, and subject identification logs. The guideline also requires documentation of monitoring visits, adverse event reports, and deviation records to support trial reconstruction and regulatory review.

Conclusion

ICH E6 is the cornerstone of GCP compliance globally and continues to evolve to address emerging trends in clinical research. Understanding its provisions is essential for sponsors, investigators, and ethics committees alike. The shift toward risk-based and digitally enabled trials in E6(R3) marks a significant advancement for the clinical research community.